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During the past three decades, deep brain stimula-
tion (DBS) has become an established treatment for
movement disorders and other indications with more
than 120,000 patients worldwide currently implanted
with a DBS device. The advent of directional leads is
a recent technological advance and has the potential
to expand the capabilities of DBS. The ability to more
accurately target and precisely control stimulation can
theoretically improve the effectiveness of DBS while
avoiding side effects, but given the novelty of this
approach there is currently no firm clinical evidence.
Hence, we feel that the thoughts and experiences of
the early adopters of this therapy, which are summa-
rized in this viewpoint, may guide the practice of
others until more evidence accumulates.
Unlike conventional DBS leads, which use cylindrical
electrodes, directional leads comprise radially segmented
electrodes that allow the stimulation field to be moved
in the plane perpendicular to the lead, or shaped using
anodes and cathodes to steer stimulation in a particular
direction, based on the needs of individual patients (Fig.
1). There are currently two commercially available sys-
tems with similar electrode designs. A principal differen-
tiator is how they deliver current: one uses a single
current source, the other multiple independent current
sources (Fig. 2). A multiple independent current-
controlled system can steer the field toward any of the
360 8 on the circumference of the lead by shifting current
in small increments between adjacent directional con-
tacts. In a single-source system, with three contacts in a
segmented row, the field depends on orientation and
shape on the impedances of the individual directional
contacts. If the impedances of the three contacts are
unequal, the current distribution is distorted toward the
contacts with lower impedances. This can be problem-
atic if the impedance of a contact unexpectedly changes,
as the geometry of activated tissue would be suddenly
altered and the clinical effects with it (Fig. 2).
Clinical Opportunities
Directional leads were developed to precisely control
the volume of tissue activated (VTA) during DBS,
which is directly related to individual outcomes. DBS
has been used successfully for many years in move-
ment disorders such as Parkinson’s disease (PD),1-3 yet
treatment may sometimes be suboptimal for several
different reasons, such as inappropriate patient selec-
tion or programming or electrode placement; two
referral centers for DBS troubleshooting have reported
that therapy failure in half of the evaluated leads was
caused by suboptimal positioning.4 Stimulation of the
------------------------------------------------------------
*Corresponding author: Dr. Michael Sch€upbach, Department of Neurol-
ogy, University Hospital–Inselspital, Freiburgstrasse, CH-3010 Bern, Swit-
zerland; Michael.Schuepbach@insel.ch
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
Funding agency: The services of the medical writer were funded by
Boston Scientific.
Relevant conflicts of interests/financial disclosures: Nothing to
report.
Received: 11 December 2016; Revised: 3 May 2017; Accepted: 14
June 2017
VC 2017 The Authors. Movement Disorders published by Wiley
Periodicals, Inc. on behalf of International Parkinson and Movement
Disorder Society.
Published online 26 August 2017 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.27096
V I E W P O I N T
Movement Disorders, Vol. 32, No. 10, 2017 1371
dorsolateral subthalamic nucleus (STN) is associated
with best motor symptom control,5,6 but excessive
stimulation of adjacent fiber tracts can cause adverse
effects such as disturbances in speech and fine-motor
control.7,8 Small lead deviations from the intended
functional target play an important role in suboptimal
efficacy6 and side effects,9 even in experienced surgical
centers.6 Even with a seemingly optimal lead position,
functional targets vary from patient to patient, and
axial displacements may still lead to adverse effects.
Some stimulation targets, such as fiber tracts, tend to
be nonspherical, making them more difficult to opti-
mally capture with conventional lead geometries.
These difficulties can be a challenge for clinicians dur-
ing patient follow-up.6
Directional leads—within limits—may address these
issues, allowing stimulation to be directed toward the
functional target and away from side-effect structures.
As such, these novel leads can widen the therapeutic
window by lowering the efficacy threshold and increas-
ing the side-effect threshold,10,11 as indicated in a recent
pilot study.12 A larger therapeutic window allows
greater programming flexibility, as the expected benefi-
cial effects of DBS may be reached at a lower current
amplitude or higher current amplitudes could be attain-
able before side effects appear11—this is important
when increasing the stimulation amplitude to optimize
DBS efficacy during follow-up.13 When used chroni-
cally, directional DBS may reduce the incidence of side
effects that cannot be tested intraoperatively (eg, gait,
cognitive, or behavioral disturbances)10 and in patients
with a narrow therapeutic window despite good
location of the lead as verified by intraoperative testing,
microrecordings, or imaging, as well as in patients oper-
ated under general anesthesia precluding clinical testing
(eg, for dysarthria). By using a directional lead, it may
thus be possible to improve outcomes and cause fewer
adverse effects, including dyskinesia in patients with
low thresholds for stimulation-induced dyskinesia.
Moreover, in addition to current steering modification
of pulse width and frequency combined with directional
stimulation opens even more strategies to test for the
best therapeutic window. However, if a concentric
spherical VTA perfectly covers the target, directional
stimulation is not needed. Therefore, if the lead is opti-
mally placed in the horizontal plane, all three contacts
in a segmented row can be activated at equal ampli-
tudes to functionally simulate a cylindrical electrode
(“ring mode”). More clinical evidence for the postu-
lated and theoretically plausible advantages of direc-
tional DBS is needed.
It may also be time to examine the standard parame-
ters used for DBS, which may change in a directional
system. For example, in general patients may currently
receive more than the minimum necessary stimulation;14
a directional lead could improve this, as directed stimu-
lation may selectively capture target volumes at lower
amplitudes. In addition, the selectivity of DBS within
the VTA may be further improved by adjusting temporal
parameters such as pulse width and frequency.15,16
Moreover, within the target region, different symptoms
tend to correspond to different substructures7 (eg,
tremor regions are distinct from bradykinesia regions).
Directional leads enable further study of the structure
and shape of the targets as well as the pathophysiologi-
cal role of microstructures within by directing the VTA
toward new subtargets. This may foster our understand-
ing of motor and nonmotor effects of DBS and of the
physiology of movement, cognition, and mood.10
Directional DBS may also be useful in smaller or non-
spherical targets that are currently investigated for other
disorders, such as the fornix for dementia,17 nonmotor
STN for obsessive-compulsive disorder,18 medial fore-
brain bundle in psychiatric disorders such as major
depression,19 and the thalamus or the pallidum for Tour-
ette syndrome.20 The fornix, for example, is too small
and thus vulnerable as a target to be directly implanted
but is stimulated by a lead adjacent to the fiber tract.
Directional DBS seems a compelling approach for this
geometry. The ability to shape and steer the VTA in the
plane perpendicular to the lead could help advance the
use of DBS in these and other potential indications.
Challenges and Future Needs
There are challenges that need to be overcome when
using directional leads. Although the surgical procedure
for a directional lead is equivalent to a conventional
FIG. 1. Visualization of how the size and shape of the volume of tissue
activated can be changed by using a directional lead in a multiple,
independent, current-controlled system. The images along the top
depict a side-on view, whereas those on the bottom display a bottom-
up view. The images on the left show all the current on a single direc-
tional contact (E25100%), whereas those on the right show the
current being split equally between two adjacent contacts within a
segmented row (E25 50% and E45 50%). The directional leads are
stimulated with 3 mA at a pulse width of 30 ms.
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lead, lead rotation should be controlled using a marker
against patient-centric anatomical landmarks using X-
ray if possible. Targeting and intraoperative standards
should not be altered from current practice, although
future visualization technology may benefit from incor-
porating patient-specific anatomical and electrophysio-
logical data. In a note of caution, the directional lead
must not be used as an excuse for lowering the precision
of surgical lead placement. Although a directional lead
may theoretically be used to compensate for suboptimal
placement, more clinical evidence for the corrective
potential of directional DBS is needed.
Another challenge is that the finer control over the
VTA afforded by directional DBS entails a more com-
plex and thus potentially more time-consuming search
for best parameter settings. Assisted programming using
patient-specific imaging and electrophysiological data
including local field potentials will help compensate for
the greater complexity of programming. Although the
use of directional settings may initially be more
demanding in centers that wish to explore the full stim-
ulation space, fewer reprogramming sessions may be
required as understanding increases regarding best prac-
tices for directional lead programming. Patient prefer-
ence is a significant part of therapy, and allowing
different settings from which they can choose (within
clinician-set parameters) may provide DBS programs
tailored to specific situations; it may also assist and
therefore shorten the clinician’s search for the best
parameter settings. Initially, use of a directional lead is
essentially the same as a conventional lead; monopolar
review can be begun in ring mode, following the same
steps used with a conventional 4-row lead. It is impor-
tant at the outset to define the “best” outcome for each
individual patient, and a benchmark for PD patients is
the levodopa response, with the exception of tremor
that may not respond to levodopa while responding to
DBS. If the “best” outcome cannot be matched in ring
mode before side effects occur, further programming
options should be used.
FIG. 2. Multiple independent current source versus single current source systems. A level of three directional contacts in 120 8 distance around an
electrode is shown. In all figures, the view is perpendicular to the electrode (drawn in orange). Of the three contacts, two are activated. The intended
distribution of the stimulation current between the two adjacent activated directional contacts is 50:50. (a) Depicts a case where the impedance is
3 kOhm on one contact and 1.5 kOhm on the other contact. The red stimulation field model shows the resulting stimulation field using a multiple
independent current control system; the blue contact shows the stimulation field using a single source system. The change in stimulation field from
red to blue indicates what may happen where the single source system is used and the impedance is initially equal at both contacts, but changes
over time to a 3:1.5 kOhm ratio. (b) Depicts a case where there is an open circuit leading to one of the contacts. The red stimulation field was the
original stimulation field (assuming equal impedance at both contacts). The blue in the left figure illustrates what happens with a single source sys-
tem, when all of the stimulation (3 mA) is sent to the other, nonopen contact. The green in the right figure shows the same scenario, but with a mul-
tiple independent current control system; in this case, the amount of current sent to the nonopen contact remains the same (1.5 mA).
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At present, when directional settings are required,
the current programming methodology relies primarily
on experienced clinical intuition and minimal use of
visual or computational guidance, potentially requiring
multiple programming sessions with the patient to
achieve optimal results.21 With increasing experience
using directional leads, programming strategies and
guidelines will become available to aid neurologists
and reduce programming time. An algorithm needs to
be developed, potentially using imaging or electro-
physiological data, to allow clinicians to quickly iden-
tify the best initial settings, which can be refined
according to each patient’s response.
Nevertheless, clinical identification of optimal stimu-
lation parameters may not be intuitively obvious with-
out computational assistance as it is inconceivable to
clinically evaluate all available stimulation settings. Fur-
thermore, some symptoms (eg, bradykinesia) may
require time to respond to changes in stimulation set-
tings. Current patient-specific visualization and com-
puter modeling software (Fig. 3) needs to be further
developed to reliably assist the choice of the most
appropriate initial parameters based on the patient’s
anatomy, thereby simplifying clinical programming
associated with directional DBS.14,21,22 In addition,
stimulation adjustment may be facilitated by patients’
use of technology-based devices for ongoing and objec-
tive assessment of symptoms such as postural control,
tremor, bradykinesia, freezing, dyskinesia, and gait.23
A constant effect of DBS is crucial and depends on
technological aspects of the system used. Electrode
impedance can vary from one electrode to another
and change over time.24 In a voltage-controlled sys-
tem, electrodes with fluctuating impedance will deliver
different amounts of stimulation at the same voltage
level; in a constant-current system, the amount of
stimulation delivered is always known, making it sim-
pler to maintain a constant VTA. However, when
multiple electrodes are used with a single-source gen-
erator, current will flow through the path of least
resistance. If there is an inopportune arrangement of
impedances, a single source system may not support
the selection of the most advantageous field. If there
are unexpected changes in impedance, the stimulation
field will shift unexpectedly as a result. Thus, a multi-
ple independent current-controlled system may be the
preferred paradigm, where each electrode is individu-
ally controlled by a dedicated current source and
impedance is not a factor. Also, as segmented electro-
des are smaller and thus inherently have higher imped-
ance,25 energy consumption may be increased when
using a single segmented electrode compared to a sin-
gle conventional cylindrical electrode at the same
amplitude. However, with a directional lead equiva-
lent activation in a preferential direction would
require lower amplitudes, thus reducing the energy
requirement. The potential for higher voltage output
and greater charge density25 with small contacts may
be a concern. Therefore, safeguards must be present
within directional systems to protect against any tissue
damage. Charge density is only explicitly controlled
with a multiple independent current-controlled system.
As clinical evidence gathers on directional lead sys-
tems, the demonstration of a clinical advantage over
conventional DBS is challenging. Because DBS is a
very effective therapy, incremental improvements by
using directional stimulation will statistically best be
demonstrated in selected patient groups likely to bene-
fit from the new therapeutic option, for example, by
choosing a modified enriched-enrolment strategy26
using a physiological predictor, for example, a narrow
therapeutic window during a monopolar review.
FIG. 3. Example of patient-specific computer modeling. Tissue activation volumes illustrate the potential utility of a directional lead system. In both
images, the green anatomical outline shows a cross section of the subthalamic nucleus (STN), the red outline shows the internal capsule, and the
orange outline shows the globus pallidus internus (GPi). (a) A nondirectional lead is placed in a clinical location, where the volume of tissue activated
shows that expected therapeutic stimulation of the STN is impossible without simultaneous activation of the internal capsule. (b) A directional lead
is placed in the same location and only a single directional contact is active, effectively steering the volume of activated tissue away from the inter-
nal capsule. In both images, the tissue is being stimulated with 2 mA at a pulse width of 60 ms. Slices perpendicular to the implanted electrode at
the mid-level of the subthalamic nucleus are shown; the z-coordinate is 2.5mm inferior.
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Conclusion
The directional lead is a new tool in the armamen-
tarium for DBS that may considerably influence our
approach to the therapy. This new technology may
help to improve the standard of DBS care for move-
ment disorder patients and may become useful in
new targets and indications. As it is not possible to
preoperatively predict whether there will be a poten-
tial for improvement of DBS outcome with direc-
tional stimulation in a given patient, implantation of
a directional lead from the outset must be weighed
against the resources required. Crucially, clinical evi-
dence that the theoretical possibilities of directional
leads indeed translate into better clinical outcomes is
needed.
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